Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related CVS
Express Scripts Outlook Improves Amid Tax Reform, CVS-Aetna Deal
ICYMI: Street Reacts To CVS-Aetna, A Crypto Play's New Investment, And Other Top Stories
CVS And Aetna: The Worst Of Sick-Care Under One Roof (Seeking Alpha)
Related RM
Benzinga's Top Upgrades, Downgrades For August 23, 2017
Benzinga's Top Upgrades, Downgrades For July 18, 2017

Analysts at Cantor Fitzgerald downgraded CVS (NYSE: CVS) from “buy” to “hold.” The target price for CVS has been lowered from $65 to $62. CVS's shares closed at $59.89 yesterday.

Jefferies downgraded Regional Management (NYSE: RM) from “buy” to “hold.” The target price for Regional Management is set to $29. Regional Management's shares closed at $31.20 yesterday.

Bank of America downgraded Marathon Oil (NYSE: MRO) from “buy” to “neutral.” The target price for Marathon Oil has been lowered from $45 to $42. Marathon Oil's shares closed at $36.88 yesterday.

Analysts at McNicoll Lewis Vlak downgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) from “buy” to “hold.” The target price for ACADIA Pharmaceuticals has been raised from $18 to $20. ACADIA's shares closed at $20.68 yesterday.

Latest Ratings for CVS

DateFirmActionFromTo
Dec 2017Deutsche BankInitiates Coverage OnBuy
Nov 2017CitigroupMaintainsNeutral
Nov 2017NeedhamUpgradesHoldBuy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (ACAD + CVS)

View Comments and Join the Discussion!

Partner Center